Review summary
Teaching objective: De novo metastatic hormone-sensitive prostate cancer in a 66-year-old Chilean poet and diplomat posted abroad, on the NCCN prostate cancer guideline, the AUA/SUO advanced prostate cancer guideline and the CMID prostate cancer monograph. Urinary symptoms and bone pain with a hard prostate and a raised PSA lead to MRI, an MRI-targeted biopsy, conventional staging (CT and bone scan) and PSMA PET/CT; the disease is classified as low volume, and the choice is continuous androgen deprivation with apalutamide plus radiotherapy to the prostate, without docetaxel. The episode covers flare protection, early PSA response and the three-month PSA, germline and somatic testing, bone health (DXA, FRAX, vitamin D, calcium, exercise, a dental check and denosumab at the osteoporosis dose), the cardiometabolic risks of androgen deprivation, apalutamide's drug interaction with amlodipine, its rash and its effect on thyroid function, hot flashes, sexual health, fatigue, mood, and care in Spanish, his first language, around his writing and diplomatic work. His documented prostate cancer, operated on in France in July 1971 while he was ambassador, frames the episode; the dispute over his death two years later is history only.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| 12 July 1904 | Born in Parral, Chile. | CLM-0001 |
| 1920 | Begins publishing under the pen name Pablo Neruda. | CLM-0002 |
| 1927 | Begins a series of consular posts in Asia and later in Buenos Aires, Barcelona and Madrid (to 1935). | CLM-0003 |
| 1945 | Elected senator of the Republic. | CLM-0003 |
| 28 December 1946 | A court judgment changes his birth name to Pablo Neruda. | CLM-0002 |
| 21 January 1971 | The Senate approves his appointment as ambassador to France. | CLM-0004 |
| July 1971 | Health problems begin; operated on for prostate cancer in France. | CLM-0005 |
| 21 October 1971 | Awarded the Nobel Prize in Literature. | CLM-0006 |
| November 1972 | Resigns as ambassador and returns to Chile. | CLM-0004 |
| 23 September 1973 | Dies at the Clínica Santa María in Santiago, twelve days after the military coup; the death certificate gives cancer cachexia. | CLM-0007, CLM-0008 |
| 8 November 2013 | Chile's medical legal service reports no relevant chemical substances in his exhumed remains. | CLM-0009 |
| October 2017 | An international forensic panel rejects cachexia as the cause of death without naming a cause. | CLM-0010, CLM-0013 |
| February 2023 | Clostridium botulinum DNA reported in a molar and bone; how it got there could not be determined. | CLM-0011, CLM-0013 |
| 20 February 2024 | The Santiago appeals court orders the investigation reopened. | CLM-0012 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Pablo Neruda was born on 12 July 1904 in the town of Parral in Chile. His father was a railway employee, and his mother, a teacher, died shortly after his birth; he spent his childhood and youth in Temuco. Anchors the true birth date. His mother's cause of death is not recorded in the sources read. |
confirmed | Pablo Neruda: Biographical. Nobel Prize in Literature 1971 supports Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports HISTMED Master Roster v3 supports |
| D | He used the pen name Pablo Neruda from 1920. The Nobel Prize biography gives his real name as Neftalí Ricardo Reyes Basoalto; the Library of the National Congress of Chile gives his birth name as Ricardo Eliecer Neftalí Reyes Basoalto and records that a court judgment of 28 December 1946 changed it to Pablo Neruda. Used for the display name and the alias. The two sources order the given names differently; the congressional biography's full form is used as the alias. |
probable | Pablo Neruda: Biographical. Nobel Prize in Literature 1971 supports Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports |
| D | Between 1927 and 1935 he held a series of honorary consulships in Burma, Ceylon, Java, Singapore, Buenos Aires, Barcelona and Madrid; in 1945 he was elected a senator of the Republic and joined the Communist Party of Chile. Anchors his long diplomatic and public life in the modern social history. |
confirmed | Pablo Neruda: Biographical. Nobel Prize in Literature 1971 supports Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports |
| D | After the 1970 presidential election he was named Chile's ambassador to France; the Senate approved the appointment on 21 January 1971 and he presented his credentials at the end of that month. He resigned the post in 1972 and returned to Chile in November 1972. Anchors his occupation and his residence in Paris at the index date (June 1971). The brief gave the posting as 1970 to 1972; the sources date the appointment to January 1971. |
confirmed | Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports Pablo Neruda (1904-1973). Memoria Chilena supports |
| D | In July 1971 he began to have health problems and was operated on for prostate cancer; during his convalescence in France he wrote Geografía infructuosa. Later reports describe him as suffering from prostate cancer at the time of his death. The documented anchor for prostate cancer in the modern episode. The congressional biography is the only source read that dates the diagnosis and the operation; the type of operation, the stage, the grade and any other treatment were not recorded in the sources read. |
probable | Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017 supports Pablo Neruda did not die of cancer after all, experts say (Associated Press) supports |
| D | The Nobel Prize in Literature was awarded to him on 21 October 1971, and he received it in Stockholm on 10 December 1971. History after the modern episode's last visit. |
confirmed | Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports Pablo Neruda (1904-1973). Memoria Chilena supports Pablo Neruda: Biographical. Nobel Prize in Literature 1971 supports |
| D | He died on 23 September 1973 at the Clínica Santa María in Santiago, aged 69, twelve days after the military coup of 11 September 1973; he had been taken there by ambulance. History after the modern episode. |
confirmed | Pablo Neruda (1904-1973). Memoria Chilena supports Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017 supports Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports |
| D | The official cause of death was cancer cachexia: wasting from his prostate cancer. The National Library of Chile's account says he died of prostate cancer. Records what the death certificate stated; whether it was correct is disputed (CLM-0013). |
confirmed | Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017 supports Pablo Neruda did not die of cancer after all, experts say (Associated Press) supports Pablo Neruda (1904-1973). Memoria Chilena supports |
| D | His remains were exhumed in 2013. In November 2013 the head of Chile's medical legal service said that no relevant chemical substances had been found that could be linked to his death, and that experts had found traces of medicine used to treat cancer. History after his death; one part of the dispute over the cause of death. |
confirmed | Forensic tests show no poison in remains of Chilean poet Pablo Neruda (Associated Press) supports Pablo Neruda did not die of cancer after all, experts say (Associated Press) supports |
| D | In October 2017 an international panel of 16 forensic experts said it was certain he had not died of cancer cachexia, as the death certificate stated; one member said there was no indication of cachexia and that he was obese at the time of death. The panel said it could neither exclude nor affirm a natural or violent cause of death, and reported potentially deadly bacteria in a sample from one of his molars. History after his death; one part of the dispute over the cause of death. The panel's statement that he was not wasted at death is consistent with a man who was not cachectic; it is not used in the modern episode. |
confirmed | Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017 supports Pablo Neruda did not die of cancer after all, experts say (Associated Press) supports |
| D | In February 2023 laboratories in Canada and Denmark reported DNA of Clostridium botulinum in a molar and in bone fragments sampled in 2015. A member of the work said the finding was not definitive and did not tell what happened; panel members said they could not determine whether he had been poisoned or how the bacterium entered his body. History after his death; the finding is consistent with poisoning but does not prove it, as the scientists said. |
confirmed | Pablo Neruda died with toxic bacteria in his body, say forensic experts. The Globe and Mail, February 15, 2023 supports Was Neruda poisoned? Probe members say inconclusive (AFP) supports |
| D | In February 2024 the Santiago appeals court unanimously ordered the investigation into his death reopened, after a judge had declined to do so in December 2023; the death certificate lists cancer. History after his death. No later outcome was found in the sources read. |
confirmed | Death of Chilean poet Pablo Neruda should be reinvestigated, court rules (Associated Press) supports |
| R | Whether he died of his prostate cancer, of another natural cause such as an infection, or of poisoning is disputed and unresolved. The death certificate gives cancer cachexia; the 2013 tests found no relevant chemical substances; the 2017 panel rejected cachexia without naming a cause; the 2023 finding of Clostridium botulinum could not show how it got there; and the investigation was reopened in 2024. The record takes neither side. The cause of death is not used in the modern episode, which is set two years before his death and does not foreshadow it. |
disputed | Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017 supports Pablo Neruda did not die of cancer after all, experts say (Associated Press) supports Forensic tests show no poison in remains of Chilean poet Pablo Neruda (Associated Press) disputes Pablo Neruda died with toxic bacteria in his body, say forensic experts. The Globe and Mail, February 15, 2023 supports Was Neruda poisoned? Probe members say inconclusive (AFP) supports Death of Chilean poet Pablo Neruda should be reinvestigated, court rules (Associated Press) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed | resolved | confirmed | active | |
| S | Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1971 | active | confirmed | both_with_link | CLM-0005 |
| S | Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compression | active | confirmed | active | CLM-0005 |
| S | Pelvic lymph node metastases: right external iliac and right obturator nodes | active | confirmed | active | CLM-0005 |
| S | Hormone-sensitive prostate cancer | active | confirmed | active | CLM-0005 |
| S | Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognition | active | confirmed | active | CLM-0005 |
| S | Essential hypertension for five years, on amlodipine | active | confirmed | active | |
| S | Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | active | |
| S | Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis) | active | confirmed | active | |
| S | Prediabetes (hemoglobin A1c 5.9%) | active | confirmed | active | |
| S | Maculopapular drug rash from apalutamide, grade 2 (about 20 percent of body surface, trunk and upper arms), eight weeks into treatment; no mucosal involvement, blistering, fever, eosinophilia or liver involvement; settled on topical steroid and an antihistamine without stopping apalutamide | resolved | confirmed | active | |
| S | Personal history of radiotherapy to the prostate (55 Gy in 20 fractions, finished three weeks before the three-month visit) | active | confirmed | active | |
| S | Raised TSH (5.4 mIU/L) with a normal free T4 on apalutamide: subclinical, under observation | active | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-06-01 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 46.8 ng/mL (high) Reference <=4 ng/mL |
http://loinc.org · 2857-1 |
| S | 2026-06-01 | Testosterone [Mass/volume] in Serum or Plasma | 468 ng/dL Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation |
http://loinc.org · 2986-8 |
| S | 2026-06-01 | Hemoglobin [Mass/volume] in Blood | 13.6 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-06-01 | Leukocytes [#/volume] in Blood by Automated count | 6.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-06-01 | Platelets [#/volume] in Blood by Automated count | 248 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-06-01 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.3 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-06-01 | Glucose [Mass/volume] in Serum or Plasma | 104 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 87 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-06-01 | Calcium [Mass/volume] in Serum or Plasma | 9.6 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-06-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-06-01 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-06-01 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 168 U/L (high) Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2026-06-01 | Albumin [Mass/volume] in Serum or Plasma | 4.1 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-06-01 | Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma | 208 U/L Reference 135-225 U/L |
http://loinc.org · 2532-0 |
| S | 2026-06-01 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9% (high) Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-06-01 | Cholesterol [Mass/volume] in Serum or Plasma | 214 mg/dL (high) Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-06-01 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-06-01 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 140 mg/dL (high) Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-06-01 | Triglyceride [Mass/volume] in Serum or Plasma | 140 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-06-01 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 ng/mL (low) Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-06-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2026-06-01 | International Prostate Symptom Score [IPSS] | 17 | http://loinc.org · 80976-4 |
| S | 2026-06-01 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | http://loinc.org · 72514-3 |
| S | 2026-06-15 | DXA Femur [T-score] Bone density | -2.1 (low) Reference -1.0 or higher is normal; -2.5 or lower is osteoporosis |
http://loinc.org · 38263-0 |
| S | 2026-06-15 | DXA Lumbar spine [T-score] Bone density | -1.4 (low) Reference -1.0 or higher is normal; -2.5 or lower is osteoporosis |
http://loinc.org · 38267-1 |
| S | 2026-06-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-06-15 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | http://loinc.org · 72514-3 |
| S | 2026-07-13 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 6.2 ng/mL (high) Reference <=4 ng/mL |
http://loinc.org · 2857-1 |
| S | 2026-07-13 | Testosterone [Mass/volume] in Serum or Plasma | 22 ng/dL (low) Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation |
http://loinc.org · 2986-8 |
| S | 2026-07-13 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-07-13 | Glucose [Mass/volume] in Serum or Plasma | 101 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 85 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-07-13 | Calcium [Mass/volume] in Serum or Plasma | 9.3 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-07-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 25 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-07-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-07-13 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 141 U/L (high) Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2026-07-13 | Albumin [Mass/volume] in Serum or Plasma | 4.1 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-07-13 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 28 ng/mL (low) Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-07-13 | Thyrotropin [Units/volume] in Serum or Plasma | 2.4 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-07-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-07-13 | International Prostate Symptom Score [IPSS] | 14 | http://loinc.org · 80976-4 |
| S | 2026-07-13 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | http://loinc.org · 72514-3 |
| S | 2026-08-10 | Leukocytes [#/volume] in Blood by Automated count | 6.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-08-10 | Eosinophils [#/volume] in Blood by Automated count | 0.3 10*3/uL Reference 0-0.5 10*3/uL |
http://loinc.org · 711-2 |
| S | 2026-08-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.97 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-08-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 86 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-08-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-08-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-09-14 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 0.18 ng/mL Reference <=4 ng/mL |
http://loinc.org · 2857-1 |
| S | 2026-09-14 | Testosterone [Mass/volume] in Serum or Plasma | 14 ng/dL (low) Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation |
http://loinc.org · 2986-8 |
| S | 2026-09-14 | Hemoglobin [Mass/volume] in Blood | 12.9 g/dL (low) Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-09-14 | Leukocytes [#/volume] in Blood by Automated count | 5.9 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-09-14 | Platelets [#/volume] in Blood by Automated count | 231 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-09-14 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-09-14 | Potassium [Moles/volume] in Serum or Plasma | 4.5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-09-14 | Glucose [Mass/volume] in Serum or Plasma | 102 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.99 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 83 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-09-14 | Calcium [Mass/volume] in Serum or Plasma | 9.2 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-09-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-09-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-09-14 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 U/L Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2026-09-14 | Albumin [Mass/volume] in Serum or Plasma | 4 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-09-14 | Thyrotropin [Units/volume] in Serum or Plasma | 5.4 mIU/L (high) Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-09-14 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2026-09-14 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.1% (high) Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-09-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-09-14 | International Prostate Symptom Score [IPSS] | 9 | http://loinc.org · 80976-4 |
| S | 2026-09-14 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 | http://loinc.org · 72514-3 |
| S | 2026-10-05 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-10-05 | Total score [Mini-Cog] | 5 | http://loinc.org · 72233-0 |
| S | 2026-10-05 | Total score [AUDIT-C] | 2 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-06-01 | Body height | 178 cm | 8302-2 | S |
| 2026-06-01 | Body weight | 92.4 kg | 29463-7 | S |
| 2026-06-01 | Body mass index (BMI) [Ratio] | 29.2 kg/m2 | 39156-5 | S |
| 2026-06-01 | Systolic blood pressure | 146 mm[Hg] | 8480-6 | S |
| 2026-06-01 | Diastolic blood pressure | 88 mm[Hg] | 8462-4 | S |
| 2026-06-01 | Heart rate | 76 /min | 8867-4 | S |
| 2026-06-01 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-06-01 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-06-15 | Body height | 178 cm | 8302-2 | S |
| 2026-06-15 | Body weight | 92 kg | 29463-7 | S |
| 2026-06-15 | Body mass index (BMI) [Ratio] | 29 kg/m2 | 39156-5 | S |
| 2026-06-15 | Systolic blood pressure | 142 mm[Hg] | 8480-6 | S |
| 2026-06-15 | Diastolic blood pressure | 86 mm[Hg] | 8462-4 | S |
| 2026-06-15 | Heart rate | 74 /min | 8867-4 | S |
| 2026-06-15 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-06-15 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-07-13 | Body height | 178 cm | 8302-2 | S |
| 2026-07-13 | Body weight | 92.8 kg | 29463-7 | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 29.3 kg/m2 | 39156-5 | S |
| 2026-07-13 | Systolic blood pressure | 152 mm[Hg] | 8480-6 | S |
| 2026-07-13 | Diastolic blood pressure | 90 mm[Hg] | 8462-4 | S |
| 2026-07-13 | Heart rate | 76 /min | 8867-4 | S |
| 2026-07-13 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-07-13 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-08-10 | Body height | 178 cm | 8302-2 | S |
| 2026-08-10 | Body weight | 93 kg | 29463-7 | S |
| 2026-08-10 | Body mass index (BMI) [Ratio] | 29.4 kg/m2 | 39156-5 | S |
| 2026-08-10 | Systolic blood pressure | 136 mm[Hg] | 8480-6 | S |
| 2026-08-10 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2026-08-10 | Heart rate | 80 /min | 8867-4 | S |
| 2026-08-10 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-10 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-09-14 | Body height | 178 cm | 8302-2 | S |
| 2026-09-14 | Body weight | 94.2 kg | 29463-7 | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 29.7 kg/m2 | 39156-5 | S |
| 2026-09-14 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 2026-09-14 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-09-14 | Heart rate | 72 /min | 8867-4 | S |
| 2026-09-14 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-14 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-10-05 | Body height | 178 cm | 8302-2 | S |
| 2026-10-05 | Body weight | 94.6 kg | 29463-7 | S |
| 2026-10-05 | Body mass index (BMI) [Ratio] | 29.9 kg/m2 | 39156-5 | S |
| 2026-10-05 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-10-05 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-10-05 | Heart rate | 70 /min | 8867-4 | S |
| 2026-10-05 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-05 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Poet and diplomat: Chile's ambassador, posted abroad, with a full schedule of official duties; writes poetry every morning and is at work on a new collection
- S Language: Spanish is his first language; fluent in French. A professional Spanish medical interpreter is used for every major discussion, with written materials in Spanish; he asked to be called Mr. Neruda
- S Tobacco: never. Alcohol: wine with dinner a few evenings a week (AUDIT-C 2). No drug use
- S Lives with his wife in the official residence; she is not named, is given no role in his care, and is not a source of history
- S Activity: walks in the city most afternoons; many official dinners each week
- S Insurance: an international health plan through his country's diplomatic service; the clinic documents his care with its usual U.S. conventions
- S Strengths: a lifetime of disciplined daily writing, curiosity, a wide circle of friends, and an ease with hard conversations
Functional status
- S Independent in all daily activities; walking limited to about 20 minutes by right hip pain; ECOG performance status 1
Mental status
- S Alert, articulate and warm; worried about what the pain means; sleep broken by pain and nocturia; PHQ-9 score 6
Allergies and medications
Allergies
- S No known allergy
Medications
- S Amlodipine 5 mg oral tablet, one tablet daily
- S Amlodipine 10 mg oral tablet, one tablet daily
- S Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain
- S Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food
- S Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeks
- S Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet daily
- S Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation
- S Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin)
- S Cetirizine 10 mg oral tablet, one tablet daily for itch
- S Atorvastatin 20 mg oral tablet, one tablet daily
Procedures and immunizations
Procedures
- S Multiparametric MRI of the prostate: gland 52 mL; 24 mm PI-RADS 5 lesion in the right peripheral zone from mid-gland to base with extraprostatic extension on the right; no seminal vesicle invasion; 13 mm right external iliac lymph node; abnormal marrow signal in the right iliac bone at the edge of the field
- S CT of the chest, abdomen and pelvis with contrast: enlarged right external iliac (13 mm) and right obturator (11 mm) lymph nodes; sclerotic lesions in the right iliac wing and the L5 vertebral body without a soft-tissue mass or canal narrowing; no lung, liver or adrenal lesions
- S Whole-body bone scan (technetium-99m): two foci of increased uptake, in the right iliac wing and L5, matching the CT; no other skeletal lesions (fewer than four bone metastases, all in the spine and pelvis: low volume)
- S MRI-ultrasound fusion transperineal biopsy of the prostate, at the urology practice: adenocarcinoma, Gleason 4+4 (Grade Group 4) in 3 of 3 targeted cores (up to 80 percent of the core) and Gleason 4+4 or 4+3 in 6 of 12 systematic cores, all on the right; 9 of 14 cores in all; perineural invasion present; no intraductal or neuroendocrine features
- S Gallium-68 PSMA PET/CT: intense uptake in the right side of the prostate, in the right external iliac and right obturator nodes, and in the right iliac wing and L5; no other nodal, bone or visceral disease
- S Bone densitometry (DXA) of the hip and lumbar spine before androgen deprivation; L5 excluded because of a metastasis
- S Image-guided intensity-modulated radiotherapy to the prostate, 55 Gy in 20 daily fractions over four weeks, for low-volume metastatic disease; no pelvic nodal or bone radiation
- S Advance care planning conversation, about 30 minutes, in Spanish with a professional interpreter, with his consent
Immunizations
- S 2020-09-21: Tdap vaccine
- S 2025-10-14: High-dose influenza vaccine, last season
- S 2026-10-05: High-dose influenza vaccine, this season
- S 2026-10-05: COVID-19 vaccine, mRNA, this season
- S 2026-10-05: Pneumococcal conjugate vaccine PCV20
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
Family history
- D mother: Died shortly after his birth; cause not recorded in the cited source
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Diagnosis, staging and a shared treatment decision within three weeks of the first visit | 2026-06-15 | completed | Biopsy, CT, bone scan and PSMA PET/CT within ten days; apalutamide started at the consultation two weeks after intake |
| Bone pain controlled, with a pain score of 2 or less and sleep restored | 2026-07-13 | completed | Pain 6 of 10 at intake, 2 of 10 at four weeks on androgen deprivation |
| PSA of 0.2 ng/mL or less within about seven months of starting treatment | 2026-09-14 | completed | PSA 46.8 to 0.18 ng/mL at three months |
| Blood pressure below 130/80 mm Hg on androgen deprivation | 2026-10-05 | completed | 152/90 at four weeks on apalutamide; 128/78 at the annual wellness visit on amlodipine 10 mg |
| Protect bone health: 25-hydroxyvitamin D of 30 ng/mL or more, calcium from food, weight-bearing exercise, and a bone-protective drug for high fracture risk | 2026-10-05 | active | Denosumab given at four weeks after a dental check; vitamin D 28 ng/mL and rising; walking daily |
| Keep his morning writing and his official duties through treatment | 2026-10-05 | completed | Writing every morning; one week of official engagements postponed during radiotherapy |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Medical oncology (genitourinary) consultation within two weeks for suspected metastatic prostate cancer: diagnosis, staging, systemic treatment, radiotherapy, bone health and genetic testing | completed | GL-NCCN-PROSTATE-2026, GL-AUA-APC-2026 |
| Diagnosis and staging: multiparametric MRI of the prostate, an MRI-targeted transperineal biopsy at the urology practice, CT of the chest, abdomen and pelvis, a bone scan, and PSMA PET/CT | completed | GL-NCCN-PROSTATE-2026, GL-AUA-APC-2026, GL-CMID-2026 |
| Bone pain: acetaminophen 1000 mg up to three times a day; spinal cord compression warning signs explained in Spanish, with same-day assessment for new leg weakness or numbness, or loss of bladder or bowel control | completed | GL-NCCN-PROSTATE-2026 |
| Care in Spanish, his first language: a professional medical interpreter for every major discussion, written plans in Spanish, appointments placed around his morning writing and his official duties | completed | GL-NCCN-PROSTATE-2026 |
| Systemic therapy: apalutamide 240 mg daily from the consultation day and leuprolide 22.5 mg every twelve weeks from one week later, continuous; docetaxel not added for low-volume disease | completed | GL-AUA-APC-2026, GL-NCCN-PROSTATE-2026, GL-TITAN-2019, GL-CHAARTED-2018 |
| Radiotherapy to the prostate, 55 Gy in 20 daily fractions, about six weeks after starting androgen deprivation, for low-volume metastatic disease | completed | GL-AUA-APC-2026, GL-NCCN-PROSTATE-2026, GL-STAMPEDE-H-2018 |
| Germline genetic testing with pre-test counseling, and somatic testing of the biopsy tissue | completed | GL-AUA-APC-2026, GL-NCCN-PROSTATE-2026 |
| Bone health on androgen deprivation: DXA and FRAX, cholecalciferol 2000 units a day, calcium 1000 to 1200 mg a day from food, weight-bearing exercise, a dental examination, then denosumab 60 mg every six months for high fracture risk; DXA again in one to two years | completed | GL-AUA-APC-2026, GL-CMID-2026, GL-CALGB90202-2014 |
| Monitoring on androgen deprivation and apalutamide: PSA and testosterone every three months, blood count and chemistry, TSH every four months, blood pressure at every visit, hemoglobin A1c and lipids, rash, falls, hot flashes, sexual health, fatigue, mood and cognition | completed | GL-CMID-2026, GL-ERLEADA-2026, GL-AUA-APC-2026 |
| Apalutamide rash: triamcinolone 0.1% cream twice daily for two weeks, cetirizine 10 mg daily, fragrance-free emollient, continue apalutamide; stop it and call the same day for blisters, peeling, mouth or eye sores, fever, or spread beyond a third of the skin | completed | GL-ERLEADA-2026, GL-NCCN-PROSTATE-2026 |
| Atorvastatin 20 mg daily for primary prevention, with a lipid panel and ALT in six to twelve weeks | completed | GL-USPSTF-STATIN-2022, GL-CMID-2026 |
Planned encounters
- 2026-06-01 — New patient with four months of urinary symptoms and six weeks of right hip and low back pain: examination, PSA and baseline tests, pain control, the staging and biopsy plan, and medical oncology referral (ENC-001)
- 2026-06-15 — Two-week review with the medical oncology consultation the same day: biopsy and staging results, the diagnosis, shared decision on treatment, the start of apalutamide, genetic testing, and bone density (ENC-002)
- 2026-07-13 — Four-week review on apalutamide and leuprolide: early PSA response, testosterone, blood pressure, pain, the dental check and the first denosumab dose, and the radiotherapy plan (ENC-003)
- 2026-08-10 — Same-day sick visit for an itchy rash on apalutamide (ENC-005, unscheduled)
- 2026-09-14 — Three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the year (ENC-004)
- 2026-10-05 — Subsequent annual wellness visit (ENC-006)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Care-plan review)
- Progress note 06 — Annual Wellness Visit, Subsequent
- Medical Oncology (genitourinary) referral
- Medical Oncology (genitourinary) consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Care-plan review) (XML)
- Progress note 06 — Annual Wellness Visit, Subsequent (XML)
- Medical Oncology (genitourinary) referral (XML)
- Medical Oncology (genitourinary) consultation (XML)
Sources
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the low-volume classification on conventional imaging with a concordant PSMA PET/CT, apalutamide rather than abiraterone or enzalutamide, no docetaxel, radiotherapy to the prostate, apalutamide started one week before leuprolide for flare protection, denosumab at the osteoporosis dose rather than a bone agent for skeletal events, the amlodipine interaction, the grade 2 rash managed without stopping apalutamide, and the missed baseline TSH. |
| provenance review | not_started | Sources: the Nobel Prize biography, the Library of the National Congress of Chile, the National Library of Chile (Memoria Chilena), and AP, AFP, CBS, Smithsonian, Globe and Mail and NPR reporting on the forensic investigations. The Fundación Pablo Neruda pages, the New York Times and The Guardian were not read. The posting to France is dated January 1971, not 1970. |
| safe messaging review | not_started | The dispute over his death is recorded as R disputed, taking no side. No relative or other real person is named in the modern episode or given a statement, decision or health fact; relatives quoted in the news reports are not used. Mood screening is synthetic and below the thresholds for a safety assessment. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.